

What is claimed is:

1. A method of treating allergic rhinitis in a human while avoiding the concomitant liability of adverse side-effects associated with the administration of non-sedating antihistamines, comprising administering to said human a therapeutically effective amount of DCL or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 wherein said adverse side-effect is cardiac arrhythmia or tumor promotion.
3. The method of claim 1 wherein said human has a higher than normal propensity for or incidence of cancer.
- 15 4. The method of claim 1, wherein interaction between DCL and a drug that inhibits cytochrome P450 is avoided.
5. The method of claim 1 wherein the amount of DCL administered is from about 0.1 mg to less than about 10 mg per day.
- 20 6. The method of claim 5 wherein the amount of DCL administered is from about 0.1 mg to about 5 mg per day.
- 25 7. The method of claim 1 wherein the amount of said DCL or a pharmaceutically acceptable salt thereof is administered together with a pharmaceutically acceptable carrier.
- 30 8. A method of treating allergic asthma in a human while avoiding the concomitant liability of adverse side-effects associated with the administration of non-sedating antihistamines, comprising administering to said human a therapeutically effective amount of DCL or a pharmaceutically acceptable salt thereof.

9. The method of claim 8 wherein said adverse side-effect is cardiac arrhythmia or tumor promotion.

10. The method of claim 8 wherein said human has a higher than normal propensity for or incidence of cancer.

11. The method of claim 8, wherein interaction between DCL and a drug that inhibits cytochrome P450 is avoided.

10 12. The method of claim 8 wherein the amount of DCL administered is from about 0.1 mg to less than about 10 mg per day.

13. The method of claim 12 wherein the amount of DCL administered is from about 0.1 mg to about 5 mg per day.

14. The method of claim 8 wherein the amount of said DCL or a pharmaceutically acceptable salt thereof is administered together with a pharmaceutically acceptable carrier.

15. A method for treating retinopathy or other small vessel diseases associated with diabetes mellitus in a human while avoiding the concomitant liability of adverse side-effects associated with the administration of non-sedating antihistamines, comprising administering to said human a therapeutically effective amount of DCL or a pharmaceutically acceptable salt thereof.

30 16. The method of treating claim 15 wherein said adverse side-effect is cardiac arrhythmia or tumor promotion.

17. The method of claim 15 wherein said human has a higher than normal propensity for or incidence of cancer.

35

18. The method of claim 15 wherein interaction between DCL and a drug that inhibits cytochrome P450 is avoided.

19. The method of claim 15 wherein the amount of DCL administered is from about 0.1 mg to less than about 10 mg per day.

5 20. The method of claim 19 wherein the amount of DCL administered is from about 0.1 mg to about 5 mg per day.

21. The method of claim 15 wherein the amount of said DCL or a pharmaceutically acceptable salt thereof is
10 administered together with a pharmaceutically acceptable carrier.

22. A method for treating cough, cold, cold-like or flu symptoms and the discomfort, headache, pain, fever and
15 general malaise associated therewith, in a human, while avoiding the concomitant liability of adverse side-effects associated with the administration of non-sedating antihistamines, comprising administering to said human a composition, said composition comprising (i) a
20 therapeutically effective amount of DCL or a pharmaceutically acceptable salt thereof, and (ii) a therapeutically effective amount of a non-steroidal antiinflammatory agent or non-narcotic analgesic, or a pharmaceutically acceptable salt thereof.

25

23. The method of claim 22 wherein said adverse side-effect is cardiac arrhythmia or tumor promotion.

24. The method of claim 22 wherein said human has a
30 higher than normal propensity for or incidence of cancer.

25. The method of claim 22, wherein interaction between DCL and a drug that inhibits cytochrome P450 is avoided.

35 26. The method of claim 22 wherein said composition further comprises from about 0.1 mg to less than about 10 mg

of DCL and from about 25 mg to about 600 mg of said anti-inflammatory or analgesic.

27. The method of claim 22, wherein said composition
5 further comprises a pharmaceutically acceptable carrier.

28. A method for treating cough, cold, cold-like or flu symptoms and the discomfort, headache, pain, fever and general malaise associated therewith, in a human, while
10 avoiding the concomitant liability of adverse side-effects associated with the administration of non-sedating antihistamines, comprising administering to said human a composition, said composition comprising (i) a therapeutically effective amount of DCL or a pharmaceutically
15 acceptable salt thereof, and (ii) a therapeutically effective amount of a decongestant or a pharmaceutically acceptable salt thereof.

29. The method of claim 28 wherein said adverse side-
20 effect is cardiac arrhythmia or tumor promotion.

30. The method of claim 28 wherein said human has a higher than normal propensity for or incidence of cancer.

25 31. The method of claim 28 wherein interaction between DCL and a drug that inhibits cytochrome P450 is avoided.

32. The method of claim 28 wherein the said composition further comprises from about 0.1 mg to less than about 10 mg
30 of said DCL and from about 5 mg to about 150 mg of said decongestant.

33. The method of claim 28, wherein said composition further comprises a pharmaceutically acceptable carrier.

35 *SnbB2* 34. A method of treating urticaria in a human while avoiding the concomitant liability of adverse side-effects

Sub B2 associated with the administration of non-sedating antihistamines, comprising administering to said human a therapeutically effective amount of DCL or a pharmaceutically acceptable salt thereof.

5

Sub C ✓ 35. The method of claim 34 wherein said adverse side-effect is cardiac arrhythmia or tumor promotion.

10 36. The method of claim 34 wherein said human has a higher than normal propensity for or incidence of cancer.

15 37. The method of claim 34, wherein interaction between DCL and a drug that inhibits cytochrome P450 is avoided.

38. The method of claim 34 wherein the amount of DCL administered is from about 0.1 mg to less than about 10 mg per day.

20 39. The method of claim 38 wherein the amount of DCL administered is from about 0.1 mg to about 5 mg per day.

25 40. The method of claim 34 wherein the amount of said DCL or a pharmaceutically acceptably salt thereof is administered together with a pharmaceutically acceptable carrier.

30 41. A method of treating symptomatic dermographism in a human while avoiding the concomitant liability of adverse side-effects associated with the administration of non-sedating antihistamines, comprising administering to said human a therapeutically effective amount of DCL or a pharmaceutically acceptable salt thereof.

35 42. The method of claim 41 wherein said adverse side-effect is cardiac arrhythmia or tumor promotion.

SEARCHED INDEXED
SERIALIZED FILED
JUN 23 1990

43. The method of claim 41 wherein said human has a higher than normal propensity for or incidence of cancer.

44. The method of claim 41, wherein interaction between 5 DCL and a drug that inhibits cytochrome P450 is avoided.

45. The method of claim 41 wherein the amount of DCL administered is from about 0.1 mg to less than about 10 mg per day.

10

46. The method of claim 42 wherein the amount of DCL administered is from about 0.1 mg to about 5 mg per day.

47. The method of claim 41 wherein the amount of said 15 DCL or a pharmaceutically acceptably salt thereof is administered together with a pharmaceutically acceptable carrier.

20

John D S

25

30

35